Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

Lymphoma

Line of Therapy: Treated with brentuximab vedotin in the second line or beyond setting, or =6 months from the last dose of brentuximab vedotin for subjects treated in the frontline setting

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Seattle Genetics, Inc

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.